Asunaprevir: Additional Phase II data

Additional data from an expanded cohort of 43 patients with HCV genotype 1b infection who were null responders or were ineligible for or intolerant to peginterferon alfa-2a and ribavirin in the open-label, Japanese Phase II AI447-017 trial showed that 77% of patients achieved an SVR defined as undetectable HCV RNA levels (<15 IU/mL) 12 weeks after completing 24 weeks of treatment with once-daily 60 mg oral daclatasvir plus twice-daily 200 mg oral asunaprevir. Specifically, 91% of prior null responders (n=21) and 64% of patients ineligible for or intolerant to peginterferon alfa-2a and ribavirin (n=22) achieved an SVR 24 weeks after the end of treatment. Rates of viral breakthrough and post-treatment relapse, all of which occurred in patients ineligible for or intolerant to peginterferon alfa-2a and ribavirin, were 7% and 9.3%, respectively. Data were presented at the European Association for the Study of the Liver meeting in Barcelona. ...